INmune Bio, Inc. announced that the company has entered into a pre-clinical research collaboration with Chinese University of Hong Kong (CUHK) to evaluate INKmune -- the company's pseudokine NK cell priming platform -- in nasopharyngeal cancer (NPC), a type of head and neck cancer. The Strategic Partnership Award for Research Collaboration, which was granted by the CUHK Office of Academic Links, is between Prof. Michael Tong at CUHK and Prof. Mark Lowdell at University College London (UCL) and Chief Scientific Officer of INMB. The project provides INMB scientists working at UCL with access to the only three proven NPC cancer cell lines to test the ability of INKmune-primed NK cells to kill NPC tumors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.08 USD | -7.91% | +8.22% | -19.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.36% | 180M | |
+20.03% | 126B | |
+23.61% | 117B | |
+23.26% | 27.52B | |
-18.07% | 20.87B | |
-15.13% | 17.01B | |
-14.81% | 16.26B | |
+9.78% | 14.56B | |
-46.10% | 15.09B | |
+52.34% | 13.89B |
- Stock Market
- Equities
- INMB Stock
- News INmune Bio, Inc.
- INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate Inkmune in Nasopharyngeal Cancer